The Pulse Check

Emyria (ASX: EMD)

Sep 10, 2026

•

6 min read

FDA invites Emyria (ASX: EMD) to speak in Washington

Jason Segal

The Pulse Check

Sep 7, 2026

•

4 min read

The Small Cap to Large Cap Batton Pass

Jason Segal

The Pulse Check

Why Australia Relies on 115 Rare Blood Donors to Save Babies

Sep 3, 2026

•

4 min read

Why Australia Relies on 115 Rare Blood Donors to Save Babies

Jason Segal

The Pulse Check

Who’s Milking Who? Inside the US Pharma Cash Cow

Sep 2, 2026

•

4 min read

Who’s Milking Who? Inside the US Pharma Cash Cow

Jason Segal

Cambium Bio (ASX: CMB)

Sight for Sore Eyes: The Cambium Bio Story (CMB)

Sep 1, 2026

•

10 min read

Sight for Sore Eyes: The Cambium Bio Story (CMB)

Jason Segal

The Pulse Check

Tetratherix (TTX) launches GLP-1 nasal spray in the US

Aug 31, 2026

•

4 min read

Tetratherix (TTX) launches GLP-1 nasal spray in the US

Jason Segal

The Pulse Check

Aug 28, 2026

•

2 min read

So, how was Armchair After Market?

Jason Segal

The Pulse Check

Aug 27, 2026

•

6 min read

The Battle for Genetic Signatures

Jason Segal

The Pulse Check

Can PAR score PAR in the next biotech readout?

Aug 26, 2026

•

4 min read

Can PAR score PAR in the next biotech readout?

Jason Segal

Cambium Bio (ASX: CMB)

One Chart to Rule Them All: AFT Pharma Story

Aug 24, 2026

•

10 min read

One Chart to Rule Them All: AFT Pharma Story

Jason Segal

The Pulse Check

Aug 21, 2026

•

3 min read

How do you like your kidneys? Ice Cold

Jason Segal

The Pulse Check

Aug 20, 2026

•

3 min read

Cancer Vaccine on the Cards

Jason Segal

The Pulse Check

Aug 19, 2026

•

3 min read

The Healthcare Cerberus Just Woke Up

Jason Segal

Neuren Pharmaceuticals (ASX: NEU)

The Orphan Drug Playbook: The Neuren Story (NEU)

Aug 18, 2026

•

10 min read

The Orphan Drug Playbook: The Neuren Story (NEU)

Jason Segal

The Pulse Check

Reporting Season: What I look for in Annual Reports

Aug 17, 2026

•

8 min read

Reporting Season: What I look for in Annual Reports

Jason Segal

The Pulse Check

Aug 14, 2026

•

2 min read

Two weeks to go...

Jason Segal

The Pulse Check

Back the Jockey: The Alterity Story (ASX: ATH)

Aug 13, 2026

•

8 min read

Back the Jockey: The Alterity Story (ASX: ATH)

Jason Segal

The Pulse Check

Aug 12, 2026

•

7 min read

Control Bionics lands on the App Store

Jason Segal

The Pulse Check

Aug 7, 2026

•

2 min read

Day 2 of Bioshares: One Year On...

Jason Segal

The Pulse Check

Aug 6, 2026

•

1 min read

Eli Lilly's $23 Billion Shopping Spree

Jason Segal

The Pulse Check

Aug 5, 2026

•

1 min read

Day 1 of Bioshares: It’s Snow Problem

Jason Segal

The Pulse Check

Aug 4, 2026

•

8 min read

The Money Equation for Biotechs

Jason Segal

The Pulse Check

Aug 3, 2026

•

9 min read

Time is Brain: The EMVision Story (EMV)

Jason Segal

The Pulse Check

Control Bionics: A Quarter’s Worth of Progress

Jul 31, 2026

•

5 min read

Control Bionics: A Quarter’s Worth of Progress

Jason Segal

The Pulse Check

The Biggest Tree in Healthcare Stands Tall

Jul 30, 2026

•

2 min read

The Biggest Tree in Healthcare Stands Tall

Jason Segal

The Pulse Check

FDA invites Emyria (ASX: EMD) to speak in Washington

The Small Cap to Large Cap Batton Pass

Why Australia Relies on 115 Rare Blood Donors to Save Babies

Who’s Milking Who? Inside the US Pharma Cash Cow

Sight for Sore Eyes: The Cambium Bio Story (CMB)

Tetratherix (TTX) launches GLP-1 nasal spray in the US

So, how was Armchair After Market?

The Battle for Genetic Signatures

Can PAR score PAR in the next biotech readout?

One Chart to Rule Them All: AFT Pharma Story

How do you like your kidneys? Ice Cold

Cancer Vaccine on the Cards

The Healthcare Cerberus Just Woke Up

The Orphan Drug Playbook: The Neuren Story (NEU)

Reporting Season: What I look for in Annual Reports

Two weeks to go...

Back the Jockey: The Alterity Story (ASX: ATH)

Control Bionics lands on the App Store

Day 2 of Bioshares: One Year On...

Eli Lilly's $23 Billion Shopping Spree

Day 1 of Bioshares: It’s Snow Problem

The Money Equation for Biotechs

Time is Brain: The EMVision Story (EMV)

Control Bionics: A Quarter’s Worth of Progress

The Biggest Tree in Healthcare Stands Tall

The Armchair Analyst